<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743013</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993BA1-01</org_study_id>
    <secondary_id>2015-005198-19</secondary_id>
    <nct_id>NCT02743013</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers</brief_title>
  <official_title>Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993, Administered Via the Multi-dose Reservoir NEXThaler® Dry Powder Inhaler and Via a HFA-pressurised Metered Dose Inhaler With and Without Valved Holding Chamber, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical pharmacology study is performed to evaluate the total systemic exposure and the&#xD;
      lung availability of CHF 5993 DPI and pMDI with and without valved holding chamber, in&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the area under the curve (AUC0-t) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Area under the curve (AUC) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>AUC 0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Maximum Plasma Concentration (Cmax) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the Maximum Plasma Concentration (Cmax) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Area Under the Curve of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Area Under the Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Maximum Plasma Concentration of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Maximum Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the number of Adverse events and adverse drug reactions</measure>
    <time_frame>72 hours after adminstration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Blood pressure</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Measurement of Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the heart rate</measure>
    <time_frame>72 hours after adminstration</time_frame>
    <description>Measurement of Heart rate</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI (replicate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI VHC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with/without Charcoal Block with Valved Holding Chamber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with/without Charcoal Block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 pMDI</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 DPI Test 1</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 DPI Test 2</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 DPI test 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 pMDI replicate</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI (replicate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber</intervention_name>
    <arm_group_label>CHF 5993 100/6/12,5 pMDI VHC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's written informed consent obtained prior to any study related procedure.&#xD;
&#xD;
          2. Ability to understand the study procedures, the risks involved, and ability to be&#xD;
             trained to use the pMDI device correctly with AIM™ (Aerosol Inhalation Monitor)&#xD;
             Vitalograph®.&#xD;
&#xD;
          3. Ability to generate sufficient PIF (at least 40 L/min) using the In-Check device&#xD;
             simulating NEXThaler® device.&#xD;
&#xD;
          4. Male and female Caucasian subjects aged 18 to 55 years inclusive.&#xD;
&#xD;
          5. Body mass index (BMI) within the range of 18 to 30 kg/m2 inclusive.&#xD;
&#xD;
          6. Non-smokers or ex-smokers who smoked &lt; 5 pack years (pack-years = the number of&#xD;
             cigarette packs per day, times the number of years) and stopped smoking &gt; 1 year prior&#xD;
             to screening.&#xD;
&#xD;
          7. Good physical and mental status, determined on the basis of the medical history and a&#xD;
             general clinical examination, at screening and before randomization.&#xD;
&#xD;
          8. Lung function measurements within normal limits (Normal values: FEV1/FVC is &gt; 0.70 and&#xD;
             FEV1 &gt; 80% predicted).&#xD;
&#xD;
          9. Female subject of non-childbearing potential (WONCBP) defined as physiologically&#xD;
             incapable of becoming pregnant (i.e. post-menopausal or permanently sterile) and&#xD;
             female subjects of childbearing potential (WOCBP) fulfilling one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  WOCBP with fertile male partners: they and/or their partner of childbearing&#xD;
                  potential must be willing to use a double barrier contraceptive method including&#xD;
                  one highly effective birth control method and one acceptable birth control method&#xD;
                  (male or female condom with or without spermicide and/or cap, diaphragm or sponge&#xD;
                  with spermicide), from the signature of the informed consent and until 3 months&#xD;
                  after follow-up visit;&#xD;
&#xD;
               -  WOCBP with non-fertile male partners: contraception is not required in this case.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood donation (equal or more than 450 ml) or blood loss, less than 8 weeks prior&#xD;
             screening or prior randomization.&#xD;
&#xD;
          2. Abnormal haemoglobin level defined as &lt; 10.5 g/dl&#xD;
&#xD;
          3. For females only: pregnant and lactating female subjects, confirmed by a positive&#xD;
             serum test at screening and/or urine test before randomization.&#xD;
&#xD;
          4. Positive HIV1 or HIV2 serology.&#xD;
&#xD;
          5. Positive results from the Hepatitis serology which indicates acute or chronic&#xD;
             Hepatitis B or Hepatitis C.&#xD;
&#xD;
          6. Unsuitable veins for repeated venipuncture.&#xD;
&#xD;
          7. Documented history of alcohol abuse within 12 months prior to screening.&#xD;
&#xD;
          8. Documented history of drug abuse within 12 months prior to screening, or positive&#xD;
             urine drug test performed at screening and/or before randomization.&#xD;
&#xD;
          9. Subjects who have a positive urine test for cotinine at screening and/or before&#xD;
             randomization.&#xD;
&#xD;
         10. Clinically relevant abnormal laboratory values, suggesting an unknown disease and&#xD;
             requiring further clinical investigation.&#xD;
&#xD;
         11. Clinically relevant and uncontrolled respiratory, cardiac, hepatic, renal,&#xD;
             gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may&#xD;
             interfere with successful completion of this protocol.&#xD;
&#xD;
         12. Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or&#xD;
             bladder neck obstruction that in the opinion of the investigator would prevent use of&#xD;
             anticholinergic.&#xD;
&#xD;
         13. Subjects with history of asthma, including childhood asthma.&#xD;
&#xD;
         14. Known intolerance/ hypersensitivity to any of the excipients contained in any of the&#xD;
             formulations used in the trial.&#xD;
&#xD;
         15. Abnormal 12-lead digitized Electrocardiogram (12-lead ECG) parameter (i.e.: QRS &gt; 120&#xD;
             msec and/or PR &gt; 220 msec and/or HR &lt; 40 bpm and/or HR &gt; 110 bpm and/or QTcF &gt; 450 ms&#xD;
             for males or QTcF &gt; 470 ms for female, considering the average from triplicate) or&#xD;
             12-lead ECG evaluated as abnormal clinical significant by the investigator, at&#xD;
             screening.&#xD;
&#xD;
         16. Abnormal Blood Pressure (i.e.: Diastolic Blood Pressure &gt; 90 mmHg and/or Systolic&#xD;
             Blood Pressure &gt; 140 mmHg, considering the average from triplicate) at screening.&#xD;
&#xD;
         17. Participation in another clinical trial where investigation drug was received less&#xD;
             than 8 weeks prior to screening.&#xD;
&#xD;
         18. Subject taking any drug treatment, including prescribed or OTC medicines as well as&#xD;
             vitamins, homeopathic remedies etc, in the 14 days before the screening, with the&#xD;
             exception of :&#xD;
&#xD;
               1. Occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days&#xD;
                  for mild non-excluding conditions);&#xD;
&#xD;
               2. Hormonal contraceptives;&#xD;
&#xD;
               3. Hormonal replacement treatment for post-menopausal women.&#xD;
&#xD;
         19. Subject taking enzyme-inducing drugs, enzyme-inhibiting drugs, biologic drugs or any&#xD;
             drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide,&#xD;
             nimesulide, ketoconazole) in the 3 months before screening.&#xD;
&#xD;
         20. Heavy caffeine drinker (&gt; 5 caffeinated beverages e.g., coffee, tea, cola per day).&#xD;
&#xD;
         21. Subject who has had a lower respiratory tract infection within 4 weeks prior to&#xD;
             screening or prior randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SGS CPU Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

